help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 9, No. 5, 546-549, September 2004; doi:10.1634/theoncologist.9-5-546
© 2004 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gammon, D.
Right arrow Articles by McCormick, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gammon, D.
Right arrow Articles by McCormick, M. J.

Hypersensitivity Reactions to Oxaliplatin and the Application of a Desensitization Protocol

David Gammona, Pankaj Bhargavab, Michael J. McCormickc

a Department of Pharmacy, b Division of Hematology/Oncology, and c Division of Pulmonary, Allergy and Critical Care Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA

Correspondence: David C. Gammon, BS.Ph., UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, Massachusetts 01655, USA. Telephone: 508-856-2915; Fax: 508-856-4141; e-mail: gammond{at}ummhc.org

Oxaliplatin (Eloxatin®; Sanofi-Synthelabo Inc.; New York, NY) is a third-generation platinum agent indicated for the treatment of colorectal cancer. Severe hypersensitivity reactions to oxaliplatin rarely occur; however, they do represent a threat to the small number of patients that are occasionally affected. We developed a desensitization protocol and successfully applied it to a patient with severe, grade 3, hypersensitivity to oxaliplatin. For patients who have mild sensitivity to oxaliplatin, slowing the run rate down and giving an antihistamine and/or a steroid usually suffice. Desensitization will help to provide the small number of patients who experience severe hypersensitivity reactions with the ability to further receive an effective therapy for their colorectal cancer. The desensitization protocol is described in detail.

Key Words. Chemotherapy • Hypersensitivity reactions • Oxaliplatin • Desensitization protocol




This article has been cited by other articles:


Home page
 Ann OncolHome page
S. W. K. Siu, R. T. T. Chan, and G. K. H. Au
Hypersensitivity reactions to oxaliplatin: experience in a single institute
Ann. Onc., February 1, 2006; 17(2): 259 - 261.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. V. Ng
Hypersensitivity Reactions to Oxaliplatin in Two Asian Patients
Ann. Pharmacother., June 1, 2005; 39(6): 1114 - 1118.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2004 by AlphaMed Press.